From June 16 to 19, 2025, the annual flagship event of the global biotechnology industry—the BIO International Convention—kicked off grandly in Boston. As the world’s most influential industry gathering, this year’s BIO attracted over 20,000 industry leaders, scientific experts, and representatives from innovative companies worldwide to collectively map out the future blueprint of biotechnology.
As a steadfast participant in the US Bio exhibition for over a decade, BiBo Pharma has witnessed its own complete transformation from conceptual innovation to industrial practice. Over the past ten years of continuous participation, we have systematically showcased the entire journey—from conceptual prototypes to implementation, and from technical validation to data accumulation—vividly illustrating the leapfrog development of ultra-large-scale bioreactors from an ideal blueprint to industrial reality.
This journey precisely mirrors a pivotal transformation in the global biopharmaceutical CDMO industry: after weathering market challenges, the sector is realigning with the fundamental pursuit of biopharmaceutical manufacturing. The entire industry is now converging on two core missions: continuously enhancing production efficiency through technological innovation to achieve capacity breakthroughs, while relentlessly optimizing cost structures to reduce manufacturing expenses through scaled production. Ultimately, these efforts translate into more affordable biologics, benefiting a broader global patient population—one of the key reasons why BiBo Pharma is attracting increasing attention.
Boston holds profound significance for BiBo Pharma. In 2014, driven by the vision of ultra-large-scale bioreactors, BiBo Pharma set sail from this city of innovation. Returning to its birthplace for US Bio 2025, BiBo unveiled groundbreaking achievements—including core process parameters and quality control data for its world-first 30,000-liter ultra-large-scale production line, along with an industry-disrupting comprehensive solution achieving “biologic manufacturing at $10 per gram.” These innovations positioned BiBo as one of the most spotlighted exhibitors during the event.
Since its initial operation in March 2024, BiBo Pharma has successfully scaled up three products to its 30,000-liter ultra-large-scale production line. Not only has the company achieved “Right on the First Time” in all production scale-ups, but it has also maintained a 100% success rate across all subsequent GMP batches in ultra-large-scale production. Remarkably, multiple key parameters have surpassed laboratory benchmarks, demonstrating exceptional process stability and large-scale manufacturing capabilities. At this year’s US Bio conference, BiBo Pharma unveiled these groundbreaking data for the first time, marking the dawn of a new era in global biopharmaceutical large-scale production.
During the exhibition, BiBo Pharma’s booth was a major crowd-puller. In just three and a half days, it welcomed over 30 partner delegations from key global markets including China, North America, Europe, Asia-Pacific, the Middle East, and South America. This global outreach not only validated the strong market competitiveness of BiBo’s decade-honed technological platform, but also demonstrated how its ultra-large-scale bioreactor technology aligns with the worldwide biopharmaceutical industry’s imperative for cost reduction and efficiency improvement.
In 2026, the US Bio convention will relocate to San Diego. BiBo Pharma has confirmed its continued participation in this premier industry event, where it will showcase further innovative achievements. From Boston to San Diego, BiBo Pharma is advancing with steadfast determination toward its vision of “reshaping the global biopharmaceutical production landscape.”
